General news

Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.

Here is the online version of our event package. Sign up to get access.

Paving the way for better diagnosis, treatment and care in pulmonary fibrosis

Here is our digital event package. Sign up to get access.

After 4 years, Radiomics is moving to LégiaPark 

Après 4 ans Radiomics déménage au LégiaPark

Na 4 jaar verhuist Radiomics naar LégiaPark

Here is the online version of our information package. Sign up to get access.

Radiomics is pleased to share the 1st edition of its newsletter series. Sign up to stay up to date with the latest news from Radiomics!

Here is the online version of our information package. Sign up to get access.

Radiomics is pleased to share its sustainability policy, the measures in place and the actions we plan to take to make a positive impact on the environment around us.

The fourth part in the series of articles about imaging-based companion diagnostics will focus on the necessary regulations and considerations and is available to read here.

The third part in the series of articles about imaging-based companion diagnostics will focus on their integration into clinics and is available to read here.

Radiomics is pleased to announce its Quality Management System has been certified to be fully compliant with EN ISO 13485:2016 Medical Devices – Quality Management Systems – Requirements for regulatory purposes) standard by the notified body IMQ.

A recent review showed that 9 out of 10 clinical trials fail to test the therapy as effective, this begs the question if all potential insights from early-stage testing are being captured and used to guide the success in late-stage research and clinical use?

The second part in the series of articles about imaging-based companion diagnostics will focus on their development and is available to read here.

Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).

The two Belgian companies will work towards a better understanding of non-small cell lung cancer biology and characterization of the tumors using of AI technology

Radiomics announced that it has secured €6 Million in a pre-series B funding led by its main investors (Epimede and Noshaq) and backed by its original funders, its management team, some banks and non-dilutive financing from Walloon Regional Authorities in support of R&D Projects.

Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.

Radiomics has produced a series of articles aimed at providing a complete overview of imaging companion diagnostics and their development pathway. The first one has now been released and is available by dropping an email to [email protected]

Radiomics installed in CHU Liege and University of Florence the first machines required for the connection to the distributed learning network in the framework of DRAGON. This project, funded by the European Commission’s Horizon 2020 program Innovative Medicine Initiative (IMI) aimed at using artificial intelligence (AI) and machine learning to develop decision support systems capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.

La société Radiomics est heureuse et fière d’annoncer la visite, ce 19 mai 2021, de Monsieur Mathieu Michel, Secrétaire d’Etat fédéral belge à la Digitalisation, chargé de la Simplification administrative, de la Protection de la vie privée et de la Régie des Bâtiments.

Radiomics is pleased to announce the official opening of its first North American sales and support office with the support of the Walloon investment support agency AWEX. The new office, established in Toronto, Ontario will kick-start the company's partnerships in the area, better accommodating pharma companies and clinicians’ needs through North America-based team members.

Wim Vos CEO of Radiomics guest at Tekna Talks: Drug discovery – from airflow around a bobsleigh to airflow in the lungs.

The TIGER consortium led by eTheRNA immunotherapies and including Radiomics, is awarded an EU Commission’s grant for an HPV 16+ vaccine clinical trial

L’Europa ha lanciato un nuovo progetto chiamato Dragon, per applicare l’intelligenza artificiale alla battaglia contro il COVID-19.

A new method to map the inner ear using artificial intelligence (AI). That is what the Belgian start-up Radiomics has developed in close collaboration with doctors and scientists from Maastricht UMC +, Maastricht University, Antwerp University Hospital (UZA) and the University of Antwerp.

Radiomics together with UZAntwerpen and UMaastricht, has developed a novel tool for the automatic identification of the inner ear on MRI

With great enthusiasm and pride, the OncoRadiomics team today unveils the company's new brand identity: ‘Radiomics’.

OncoRadiomics, spin-off de l’Université de Maastricht installée à Liège et spécialisée dans le développement d’outils innovants de radiométrie, devient Radiomics afin que cette nouvelle identité corresponde davantage à ses projets de développement et ses objectifs de croissance.

Radiomics is glad to start the new year 2021 announcing and welcoming its new Chief Commercial Officer (CCO) Carlos Contreras Meca!

Radiomics developed a fully automated AI framework to extract radiomics features to classify COVID-19 infected patients from standard-of-care medical images (CT).

Presentation of our work on the prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients

The DRAGON project led by Radiomics in partnership with 18 high-tech SMEs, academic research institutes, biotech and pharma partners, affiliated patient-centred organisations and professional societies from Belgium, Italy, the Netherlands, Switzerland and the UK, has been selected for funding by the Innovative Medicines Initiative (IMI), with an evaluation score placing it in the 95% percentile.

Radiomics is glad to welcome its new Chief Medical Officer, Mariaelena Occhipinti!